Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health

Journal of Andrology

Volumn 29, Issue 1, 2008, Pages 3-14

  Burnett, Arthur L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANDROGEN DEFICIENCY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; MOLECULAR INTERACTION; NONHUMAN; PENILE FIBROSIS; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; MALE; PENILE DISEASES; PENIS; PHOSPHODIESTERASE INHIBITORS;

EID: 38049100849     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.107.003483     Document Type: Review

References (106)

1. Ahn GJ, Sohn YS, Kang KK, Ahn BO, Kwon JW, Kang SK, Lee BC, Hwang WS. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. Int J Impot Res. 2005;17: 134-141.
2. Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res. 2001;13(suppl 3):S8-S17.
3. Aversa A, Bruzziches R, Pili M, Spera G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des. 2006;12:3467-3484.
4. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol. 2003;58:632-638.
5. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2:411-422.
6. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
7. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabe J, Burgess G, Wayman C, Alexandre L, Guiliano F. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol. 2005;47:87-91.
8. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
9. Bettocchi C, Palumbo F, Cormio L, Ditonno P, Battaglia M, Selvaggi FP. The effects of androgen depletion on human erectile function: a prospective study in male-to-female transsexuals. Int J Impot Res. 2004;16:544-546.
10. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol. 2007;51:1732-1740.
11. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23: 168-175.
12. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47-52.
13. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005a;293:2648-2653.
14. Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res. 2004;16(suppl 1):S15-S19.
15. Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005b;96:29M-31M.
16. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod. 1995;52:485-489.
17. Burnett AL. Therapy insight: priapism associated with hematologic dyscrasias. Nat Clin Pract Urol. 2005c;2:449-456.
18. Burnett AL. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction? Urology. 2005d;65:224-230.
19. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3: 1077-1084.
20. Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE. Non-cholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl. 2002;23:92-97.
21. Buvat J, van Ahlen H, Schmitt H, Chan M, Kuepfer C, Varanese L. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. J Sex Med. 2006;3:512-520.
22. Caretta N, Palego P, Ferlin A, Garolla A, Bettella A, Selice R, Foresta C. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol. 2005;48:326-331.
23. Carson CC. Long-term use of sildenafil. Expert Opin Pharmacother. 2003;4:397-405.
24. Carson CC. PDE5 inhibitors: are there differences? Can J Urol. 2006;13(suppl 1):34-39.
25. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005;102: 1661-1666.
26. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489-509.
27. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004;16(suppl 1):S4-S7.
28. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999;274:13729-13732.
29. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem. 2000;267:2760-2767.
30. Das S, Maulik N, Das DK, Kadowitz PJ, Bivalacqua TJ. Cardioprotection with sildenafil, a selective inhibitor of cyclic 3′,5′- monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res. 2002;28:213-219.
31. De Young L, Yu D, Freeman D, Brock GB. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res. 2003;15: 347-354.
32. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002;25:1336-1339.
33. El-Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol. 2001;166: 927-931.
34. Esposito K, Ciotola M, Giugliano F, De Sio M, Giugliano G, D'Armiento M, Giugliano D. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18:405-410.
35. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978-2984.
36. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006a;68:429-435.
37. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 2006b;97:625-633.
38. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J. Gonzalez-Cadavid NF. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007;76:915-923.
39. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Vinanzi C, Ferlin A. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol. 2007;51:1411-1419.
40. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, Corbin JD. Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem. 2002;277: 47581-47587.
41. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001;65:1-52.
42. Gontero P, Fontana F, Zitella A, Montorsi F, Frea B. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. BJU Int. 2005;95:359-365.
43. Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl. 2006;8:3-9.
44. Gopal VK, Francis SH, Corbin JD. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem. 2001;268:3304-3312.
45. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001;22:793-797.
46. Handelsman DJ, Zajac JD. 11: Androgen deficiency and replacement therapy in men. Med J Aust. 2004;180:529-535.
47. Ignarro LJ. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol. 1990;67:1-7.
48. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun. 1990;170:843-850.
49. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89:3813-3817.
50. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S, Peled H, Pollick C, Choudhary R, Rosen R, Padma-Nathan H. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170:S46-S50.
51. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, Carson C 3rd, Cheitlin M, Debusk R, Fonseca V, Ganz P, Goldstein I, Guay A, Hatzichristou D, Hollander JE, Hutter A, Katz S, Kloner RA, Mittleman M, Montorsi F, Montorsi P, Nehra A, Sadovsky R, Shabsigh R. Sexual dysfunction and cardiac risk (the second Princeton Consensus Conference). Am J Cardiol. 2005;96:313-321.
52. Kotera J, Francis SH, Grimes KA, Rouse A, Blount MA, Corbin JD. Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. Front Biosci. 2004;9:378-386.
53. Koupparis AJ, Jeremy JY, Muzaffar S, Persad R, Shukla N. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int. 2005;96:423-427.
54. Kukreja RC. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Pharmacol. 2007;150:538-540.
55. Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med. 2007;4:908-916.
56. Levien TL. Phosphodiesterase inhibitors in Raynaud's phenomenon. Ann Pharmacother. 2006;40:1388-1393.
57. Lewis RW, Mills TM. Effect of androgens on penile tissue. Endocrine. 2004;23:101-105.
58. Lin CS, Chow S, Lau A, Tu R, Lue TF. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res. 2002;14:15-24.
59. Lin CS, Chow S, Lau A, Tu R, Lue TF. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun. 2001;280:684-692.
60. Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med. 2005;2:478-491.
61. Lin G, Xin ZC, Lue TF, Lin CS. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol. 2003;170:S15-S18.
62. Lincoln TM, Hall CL, Park CR, Corbin JD. Guanosine 3′:5′- cyclic monophosphate binding proteins in rat tissues. Proc Natl Acad Sci U S A. 1976;73:2559-2563.
63. Marin R, Escrig A, Abreu P, Mas M. Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol Reprod. 1999;61:1012-1016.
64. McMahon C. Comparison of efficacy, safety, and tolerability of ondemand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2:415-425.
65. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292-300.
66. Mills TM. Vasoconstriction and vasodilation in erectile physiology. Curr Urol Rep. 2002;3:477-483.
67. Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen H, Wespes E, Cordell WH, Chan M, Lembo D, Varanese L. An evaluation of an alternative dosing regimen with tadalafil, 3 times/ week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol. 2005;47:846-854.
68. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID; Erectile Dysfunction Guideline Update Panel. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol. 2005;174:230-239.
69. Montorsi F, Maga T, Strambi LF, Salonia A, Barbieri L, Scattoni V, Guazzoni G, Losa A, Rigatti P, Pizzini G. Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology. 2000;56:906-911.
70. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145:2253-2263.
71. Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005;2:532-540.
72. Munarriz R, Park K, Huang YH, Saenz de Tejada I, Moreland RB, Goldstein I, Traish AM. Reperfusion of ischemic corporal tissue: physiologic and biochemical changes in an animal model of ischemic priapism. Urology. 2003;62:760-764.
73. Musicki B, Champion HC, Becker RE, Kramer MF, Liu T, Sezen SF, Burnett AL. In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect. J Urol. 2005a;174:1493-1496.
74. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol. 2005b;68:226-232.
75. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
76. Okada D, Asakawa S. Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. Biochemistry. 2002;41:9672-9679.
77. Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G. et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2004a; 1:128-140.
78. Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep. 2004b;5:467-471.
79. Palmer MJ, Bell AS, Fox DN, Brown DG. Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem. 2007;7:405-419.
80. Patel MD, Katz SD. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. Am J Cardiol. 2005;96: 47M-51M.
81. Porst H, Giuliano F, Glina S, Ralph D, Casabe AR, Elion-Mboussa A, Shen W, Whitaker JS. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351-359.
82. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP 3rd, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007;19:95-103.
83. Rajfer J, Gore JL, Kaufman J, Gonzalez-Cadavid N. Case report: avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. J Sex Med. 2006;3:173-176.
84. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J Androl. 1997;18:110-115.
85. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005;47:214-220.
86. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem. 2002;277: 3310-3317.
87. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93:280-291.
88. Salva Lacombe P, Garcia Vicente JA, Costa Pages J, Lucio Morselli P. Causes and problems of nonresponse or poor response to drugs. Drugs. 1996;51:552-570.
89. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res. 2007;19:139-148.
90. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203: 2691-2702.
91. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol. 1997;15:21-26.
92. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658-663.
93. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89:251-253.
94. Sommer F, Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol. 2005;23:385-392.
95. Steers WD. Tachyphylaxis and phosphodiesterase type 5 inhibitors. J Urol. 2002:168:207.
96. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3:382-404.
97. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN, Huang YH, Goldstein I. Effects of medical or surgical castration on erectile function in an animal model. J Androl. 2003;24: 381-387.
98. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140:1861-1868.
99. Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds. Mol Pharmacol. 1999;56: 124-130.
100. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229-244.
101. Vignozzi L, Filippi S, Morelli A, Ambrosini S, Luconi M, Vannelli GB, Donati S, Crescioli C, Zhang XH, Mirone V, Forti G, Maggi M. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med. 2006;3:419-431.
102. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83:3C-12C.
103. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem. 2006;281:21469-21479.
104. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006;60:967-975.
105. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006;38:61-68.
106. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol. 2005;47:409-416.